These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33068194)

  • 1. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
    Okura M; Ida N; Yamauchi T
    Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
    Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
    Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
    Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
    Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).
    Otsuyama K; Asaoku H; Kawano MM
    Int J Hematol; 2006 Jan; 83(1):39-43. PubMed ID: 16443550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas.
    Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM
    Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
    ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
    Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
    Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A
    Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2019 Sep; 60(9):2152-2157. PubMed ID: 30887866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis.
    Matsuda M; Gono T; Shimojima Y; Hoshii Y; Ikeda S
    Amyloid; 2003 Jun; 10(2):110-6. PubMed ID: 12964418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma expressing CD19(+)CD56(-) phenotype.
    Sahara N; Ihara M; Ono T; Tamashima S; Matsui H; Takeshita A; Ohno R
    Am J Hematol; 2000 Aug; 64(4):311-3. PubMed ID: 10911386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
    Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
    Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth mechanism of human myeloma cells by interleukin-6.
    Kawano MM; Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X
    Int J Hematol; 2002 Aug; 76 Suppl 1():329-33. PubMed ID: 12430875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.
    Suzuki K; Yano S; Nishiwaki K; Sano K; Shimada T; Yahagi Y; Ogasawara Y; Sugiyama K; Takahara S; Saito T; Kasama K; Minami J; Yokoyama H; Kamiyama Y; Katsube A; Masuoka H; Katori M; Machishima T; Ouchi A; Dobashi N; Kaito K; Usui N; Aiba K
    Cancer Med; 2016 Nov; 5(11):3051-3058. PubMed ID: 27734595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.